Cargando…

Factors associated with receipt of second-line recurrent or metastatic cervical cancer treatment in the United States: A retrospective administrative claims analysis

PURPOSE: Contemporary, real-world data on eligible patients receiving treatment following progression on first-line (1L) recurrent or metastatic cervical cancer (r/mCC) therapy are needed to inform treatment algorithms and identify potential gaps in the r/mCC care continuum. METHODS: This study esti...

Descripción completa

Detalles Bibliográficos
Autores principales: Sonawane, Kalyani, Castellano, Tara, Washington, Christina, Ting, Jie, Surinach, Andy, Kirshner, Carol, Chhatwal, Jagpreet, Ayer, Turgay, Moore, Kathleen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9731386/
https://www.ncbi.nlm.nih.gov/pubmed/36506039
http://dx.doi.org/10.1016/j.gore.2022.101101
_version_ 1784845889779531776
author Sonawane, Kalyani
Castellano, Tara
Washington, Christina
Ting, Jie
Surinach, Andy
Kirshner, Carol
Chhatwal, Jagpreet
Ayer, Turgay
Moore, Kathleen
author_facet Sonawane, Kalyani
Castellano, Tara
Washington, Christina
Ting, Jie
Surinach, Andy
Kirshner, Carol
Chhatwal, Jagpreet
Ayer, Turgay
Moore, Kathleen
author_sort Sonawane, Kalyani
collection PubMed
description PURPOSE: Contemporary, real-world data on eligible patients receiving treatment following progression on first-line (1L) recurrent or metastatic cervical cancer (r/mCC) therapy are needed to inform treatment algorithms and identify potential gaps in the r/mCC care continuum. METHODS: This study estimated the prevalence and predictors of second-line (2L) r/mCC therapy among 1L-treated patients using the 2015–2020 IBM MarketScan® commercial claims database. Women ≥ 18 years diagnosed with cervical cancer and treated with first-line systemic therapies were identified and followed for 12 months from their 1L therapy end date. Women with claims for a new therapy after 60 days but no later than 365 days from the end of 1L treatment were identified as those who progressed and received 2L therapy for r/mCC. Descriptive statistics examined baseline cohort characteristics and multivariable logistic regression model examined the factors associated with receiving 2L treatment. RESULTS: We identified 384 1L-treated patients with r/mCC with ≥ 12 months of follow-up post-1L treatment. During follow-up, over half (51.0 %) of the 1L-treated r/mCC patients received 2L treatment. Patients from the South and Midwest had a lower likelihood of receiving 2L treatment compared with those living in the Northeast (adjusted odds ratio [aOR] = 0.43; 0.23–0.84) and (aOR = 0.52; 0.28–0.95, respectively). Patients not treated with bevacizumab in 1L were also less likely to receive 2L therapy (aOR = 0.65; 0.43–0.99). CONCLUSION: Additional research and targeted outreach efforts are needed to understand geography-, population-, or practice-specific barriers impacting access to 2L therapy among patients with r/mCC.
format Online
Article
Text
id pubmed-9731386
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-97313862022-12-09 Factors associated with receipt of second-line recurrent or metastatic cervical cancer treatment in the United States: A retrospective administrative claims analysis Sonawane, Kalyani Castellano, Tara Washington, Christina Ting, Jie Surinach, Andy Kirshner, Carol Chhatwal, Jagpreet Ayer, Turgay Moore, Kathleen Gynecol Oncol Rep Short Communication PURPOSE: Contemporary, real-world data on eligible patients receiving treatment following progression on first-line (1L) recurrent or metastatic cervical cancer (r/mCC) therapy are needed to inform treatment algorithms and identify potential gaps in the r/mCC care continuum. METHODS: This study estimated the prevalence and predictors of second-line (2L) r/mCC therapy among 1L-treated patients using the 2015–2020 IBM MarketScan® commercial claims database. Women ≥ 18 years diagnosed with cervical cancer and treated with first-line systemic therapies were identified and followed for 12 months from their 1L therapy end date. Women with claims for a new therapy after 60 days but no later than 365 days from the end of 1L treatment were identified as those who progressed and received 2L therapy for r/mCC. Descriptive statistics examined baseline cohort characteristics and multivariable logistic regression model examined the factors associated with receiving 2L treatment. RESULTS: We identified 384 1L-treated patients with r/mCC with ≥ 12 months of follow-up post-1L treatment. During follow-up, over half (51.0 %) of the 1L-treated r/mCC patients received 2L treatment. Patients from the South and Midwest had a lower likelihood of receiving 2L treatment compared with those living in the Northeast (adjusted odds ratio [aOR] = 0.43; 0.23–0.84) and (aOR = 0.52; 0.28–0.95, respectively). Patients not treated with bevacizumab in 1L were also less likely to receive 2L therapy (aOR = 0.65; 0.43–0.99). CONCLUSION: Additional research and targeted outreach efforts are needed to understand geography-, population-, or practice-specific barriers impacting access to 2L therapy among patients with r/mCC. Elsevier 2022-11-05 /pmc/articles/PMC9731386/ /pubmed/36506039 http://dx.doi.org/10.1016/j.gore.2022.101101 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Short Communication
Sonawane, Kalyani
Castellano, Tara
Washington, Christina
Ting, Jie
Surinach, Andy
Kirshner, Carol
Chhatwal, Jagpreet
Ayer, Turgay
Moore, Kathleen
Factors associated with receipt of second-line recurrent or metastatic cervical cancer treatment in the United States: A retrospective administrative claims analysis
title Factors associated with receipt of second-line recurrent or metastatic cervical cancer treatment in the United States: A retrospective administrative claims analysis
title_full Factors associated with receipt of second-line recurrent or metastatic cervical cancer treatment in the United States: A retrospective administrative claims analysis
title_fullStr Factors associated with receipt of second-line recurrent or metastatic cervical cancer treatment in the United States: A retrospective administrative claims analysis
title_full_unstemmed Factors associated with receipt of second-line recurrent or metastatic cervical cancer treatment in the United States: A retrospective administrative claims analysis
title_short Factors associated with receipt of second-line recurrent or metastatic cervical cancer treatment in the United States: A retrospective administrative claims analysis
title_sort factors associated with receipt of second-line recurrent or metastatic cervical cancer treatment in the united states: a retrospective administrative claims analysis
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9731386/
https://www.ncbi.nlm.nih.gov/pubmed/36506039
http://dx.doi.org/10.1016/j.gore.2022.101101
work_keys_str_mv AT sonawanekalyani factorsassociatedwithreceiptofsecondlinerecurrentormetastaticcervicalcancertreatmentintheunitedstatesaretrospectiveadministrativeclaimsanalysis
AT castellanotara factorsassociatedwithreceiptofsecondlinerecurrentormetastaticcervicalcancertreatmentintheunitedstatesaretrospectiveadministrativeclaimsanalysis
AT washingtonchristina factorsassociatedwithreceiptofsecondlinerecurrentormetastaticcervicalcancertreatmentintheunitedstatesaretrospectiveadministrativeclaimsanalysis
AT tingjie factorsassociatedwithreceiptofsecondlinerecurrentormetastaticcervicalcancertreatmentintheunitedstatesaretrospectiveadministrativeclaimsanalysis
AT surinachandy factorsassociatedwithreceiptofsecondlinerecurrentormetastaticcervicalcancertreatmentintheunitedstatesaretrospectiveadministrativeclaimsanalysis
AT kirshnercarol factorsassociatedwithreceiptofsecondlinerecurrentormetastaticcervicalcancertreatmentintheunitedstatesaretrospectiveadministrativeclaimsanalysis
AT chhatwaljagpreet factorsassociatedwithreceiptofsecondlinerecurrentormetastaticcervicalcancertreatmentintheunitedstatesaretrospectiveadministrativeclaimsanalysis
AT ayerturgay factorsassociatedwithreceiptofsecondlinerecurrentormetastaticcervicalcancertreatmentintheunitedstatesaretrospectiveadministrativeclaimsanalysis
AT moorekathleen factorsassociatedwithreceiptofsecondlinerecurrentormetastaticcervicalcancertreatmentintheunitedstatesaretrospectiveadministrativeclaimsanalysis